Luis Ortega-Paz
Overview
Explore the profile of Luis Ortega-Paz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bobi J, Jimenez-Trinidad F, Ortega-Paz L, Cortes-Serra N, Lazaro I, Rodriguez J, et al.
Eur J Clin Invest
. 2025 Mar;
:e70022.
PMID: 40045754
Objective: Circulating extracellular vesicles (EVs) have a great impact on human health as biomarkers and messengers in intercellular signalling. We aimed to determine how the miRNA profile of circulating EVs...
2.
Ortega-Paz L, Rollini F, Franchi F, Sibbing D, Angiolillo D
Interv Cardiol Clin
. 2024 Dec;
13(4S):e1-e30.
PMID: 39674676
Antiplatelet therapy involving aspirin and a P2Y receptor inhibitor is fundamental in managing patients with atherothrombotic disease. Switching between P2Y inhibitors is frequently observed in clinical settings for various reasons,...
3.
Ruberti A, Ortega-Paz L, Brugaletta S
Med Clin (Barc)
. 2024 Dec;
PMID: 39665901
No abstract available.
4.
Lakkireddy D, Angiolillo D, Charlton-Ouw K, Jefferson B, Peeran S, Bisharat M, et al.
Clin Cardiol
. 2024 Dec;
47(12):e70039.
PMID: 39663755
Introduction: Coronary artery disease (CAD) and peripheral artery disease (PAD) increase the risks of cardiovascular events and death. Digital health technologies are rapidly expanding to improve healthcare quality and access....
5.
Occhipinti G, Ortega-Paz L, Franchi F, Rollini F, Capodanno D, Brugaletta S, et al.
Expert Opin Drug Metab Toxicol
. 2024 Oct;
21(1):29-40.
PMID: 39407420
Introduction: Cangrelor, the only intravenous platelet P2Y receptor inhibitor, is characterized by a prompt and potent platelet inhibition, with a rapid offset of action. Large-scale clinical trials have shown that...
6.
Starnecker F, Coughlan J, Jensen L, Bar S, Kufner S, Brugaletta S, et al.
Eur J Clin Invest
. 2024 Oct;
55(1):e14323.
PMID: 39351821
Background: Investigations of very long-term outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) according to clinical presentation are scarce. Here, we investigated the 10-year clinical outcomes of patients...
7.
8.
Ortega-Paz L, Franchi F, Rollini F, Galli M, Been L, Ghanem G, et al.
JACC Basic Transl Sci
. 2024 Aug;
9(7):865-876.
PMID: 39170956
This prospective ex vivo and in vitro pharmacodynamic (PD)/pharmacokinetic investigation was conducted in patients with diabetes mellitus with (n = 31) and without chronic kidney disease (n = 30). PD...
9.
Ortega-Paz L, Bikdeli B
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
3(1):101221.
PMID: 39131983
No abstract available.
10.
Galli M, Occhipinti G, Ortega-Paz L, Franchi F, Rollini F, Brugaletta S, et al.
Drugs
. 2024 Jul;
84(9):1055-1070.
PMID: 39073551
Significant advancements have shaped the landscape of anticoagulant therapy in the past two decades, including the introduction of direct oral anticoagulants (DOACs), characterized by favorable safety and efficacy profiles and...